HighTower Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

HighTower Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,521	Closed	-$13K	–	2438
2017 Q3	$13K	Hold	10,521	–	–	﹤0.01%	2143
2017 Q2	$17K	Buy	+10,521	New	+$23.6K	﹤0.01%	2085
2017 Q1	–	Sell	-9,138	Closed	-$49K	–	2206
2016 Q4	$49K	Buy	9,138 +1,400	+18%	+$24.2K	﹤0.01%	1818
2016 Q3	$195K	Buy	7,738 +1,475	+24%	+$37.2K	﹤0.01%	1661
2016 Q2	$156K	Buy	6,263 +463	+8%	+$13.1K	﹤0.01%	1545
2016 Q1	$166K	Buy	5,800 +1,112	+24%	+$30.2K	﹤0.01%	1841
2015 Q4	$175K	Buy	4,688 +141	+3%	+$6.22K	﹤0.01%	1782
2015 Q3	$220K	Buy	+4,547	New	+$318K	﹤0.01%	1602
2015 Q2	–	Sell	-5,872	Closed	-$210K	–	1790
2015 Q1	$210K	Sell	5,872 -1,162	-17%	-$34.4K	﹤0.01%	1417
2014 Q4	$89K	Buy	+7,034	New	+$102K	﹤0.01%	1481

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

HighTower Advisors's ANTH Position: Q4 2017 in Review

HighTower Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 10,521 shares — an estimated $13K sold.

HighTower Advisors first reported a position in ANTH in Q4 2014 and held it in 10 quarters. The position peaked at $220K in Q3 2015. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

HighTower Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
HighTower Advisors sold 10,521 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $13K.
HighTower Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
HighTower Advisors's Anthera Pharmaceuticals, Inc. position peaked at $220K in Q3 2015.
37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on HighTower Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.